Registry update — unassessed
A Phase 1/2, Randomized Clinical Study to Assess the Safety and Efficacy of Sirolimus in Patients With Newly Diagnosed, Treatment-Naive Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Trial registry update: TERMINATED. No results reported in the supplied registry record.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jan 10, 2013 · Discovered: Sep 19, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The abstract does not report efficacy outcomes or effect sizes, so no conclusions can be drawn about whether rapamycin actually improved vision or slowed disease progression
- The abstract does not report sample size or safety data, preventing assessment of whether adverse events were rare or common
- Without comparison to standard treatments or control groups, efficacy relative to existing age-related macular degeneration therapies cannot be determined from this abstract
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Patients with newly diagnosed, treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration
- Primary outcome
- Safety and efficacy of ocular sirolimus formulation
- Effect size
- —
- Significance
- Not reported
- Journal
- Santen Inc.
- Published
- Jan 10, 2013
Sources
Primary source
- Santen Inc. ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
A Phase 1/2, Randomized Clinical Study to Assess the Safety and Efficacy of Sirolimus in Patients With Newly Diagnosed, Treatment-Naive Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation via different injection routes in patients with treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.